Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Conmed (CNMD) Research & Development (2016 - 2026)

Conmed filings provide 17 years of Research & Development readings, the most recent being $16.3 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 26.15% to $16.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $59.3 million, a 10.21% increase, with the full-year FY2025 number at $55.9 million, up 2.68% from a year prior.
  • Research & Development hit $16.3 million in Q1 2026 for Conmed, up from $14.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $16.3 million in Q1 2026 to a low of $10.7 million in Q1 2022.
  • Median Research & Development over the past 5 years was $13.6 million (2024), compared with a mean of $13.3 million.
  • Biggest five-year swings in Research & Development: dropped 6.07% in 2024 and later increased 26.15% in 2026.
  • Conmed's Research & Development stood at $12.2 million in 2022, then rose by 14.8% to $14.0 million in 2023, then dropped by 6.07% to $13.2 million in 2024, then increased by 13.08% to $14.9 million in 2025, then grew by 9.62% to $16.3 million in 2026.
  • The last three reported values for Research & Development were $16.3 million (Q1 2026), $14.9 million (Q4 2025), and $13.9 million (Q3 2025) per Business Quant data.